Titlebook: Immunotherapy for Pediatric Malignancies; Juliet C. Gray,Aurélien Marabelle Book 2018 Springer International Publishing Switzerland 2018 A

儲備

Introduction to Pediatric Cancer Immunotherapy,points PD-1/PD-L1 and CTLA-4/B7 are providing durable responses and overall survival benefits in multiple relapsing/refractory adult cancer types. Novel immunotherapies such as oncolytic viruses and adoptive CAR-T cells are also becoming approved immune therapies and revolutionize the world of drug

條街道往前推

Overcoming Immune Suppression in the Tumor Microenvironment: Implications for Multi-modal Therapy,immunosuppressive tumor microenvironment. This problem is more than just the suppression of effector T cells, but also includes profound defects in the inflammatory milieu and immunogenic antigen-presenting cells that are required to drive T cell activation. To date, much of the field of immunothera

Instantaneous

小步走路

Overview of Monoclonal Antibody Therapies,argeting almost any antigen of choice, opening the door to widespread application. Since the first monoclonal antibody was licensed for clinical use 30 years ago, there has been an exponential growth in our knowledge of how they may be used therapeutically, particularly in the treatment to cancer. T

性上癮

sinoatrial-node

Monoclonal Antibodies Directly Targeting Antigens on Solid Tumours,5 to clinical applicability and finally to approved drugs for cancer immunotherapy in the late 1990s. The number of approved Mabs in adult oncology is dramatically increasing over the years. Although approval rates in paediatric indications stay far behind, the clinical utility of Mabs in paediatric

感染

Monoclonal Antibodies Targeting the Immune System,f immune cancer evasion has enabled the development of new cancer immunotherapy targeted to inhibitory immune checkpoints: PD-1, PD-L1 and CTLA4. Dramatic results were obtained in advanced melanoma (34% survival at 5 years with anti-PD-1) and non-small cell lung cancer, and proof of efficacy has bee

織布機(jī)

,Adoptive T Cell Therapies for Children’s Cancers,cacy of T cells in paediatric cancer was seen in the “graft-versus-leukaemia” effects following allogeneic bone marrow transplantation. Subsequently, the approach has been trialled in solid tumours following genetic modification of T-cells to retarget them against cancer. Optimised T-cell products c

–吃

bifurcate